Access to HCV medicines and patent law Ellen ‘t Hoen, Medicines Law & Policy Seychelles September 2014.

Slides:



Advertisements
Similar presentations
Gilead’s Tech Transfer Partnerships and IP in India
Advertisements

Overcoming Patent barriers to hepatitis C treatment The Hepatitis C Treatment Revolution Expanding Access to HIV Co-Infected and Beyond UNITAID, MSF, WHO.
Traitement de l’Hépatite C Sans Interféron Patrick Marcellin.
BUY Recommendation: Gilead Sciences (GILD). Company Overview Gilead Sciences, Inc. is a research-based biopharmaceutical company found in 1987 that discovers,
Differences in the availability of medicines used for chronic and acute conditions in developing countries Alexandra Cameron International Conference on.
Innovation and Access to Medicines: A Case Study for HIV/AIDS and Hepatitis C Dr Manica Balasegaram, WIPO Seminar, 2014.
1 1 Access to medicines in Europe Médecins du monde – Doctors of the World International Network François Berdougo – Harm Reduction Working Group.
XIX International AIDS Conference July 2012 Washington DC, USA The Brazilian experience: the campaign for access to lopinavir/ritonavir and efavirenz compulsory.
WIPO Global Challenges Seminar Innovation and Access: A Case Study for HIV/AIDS and Hepatitis C Gregg Alton, Executive Vice President, Corporate and Medical.
HCV drug pricing « The future of HIV & HCV Treatment : Patents, pricing and pharma, Special session » Pauline Londeix XX International AIDS conference.
“Using Competition Law to Promote Access to Health Technologies” Access to Innovation: Making Generic Versions of Newer ARVs Affordable 24 July 2014 Melbourne,
Health Professional Students AIDS Advocacy Network Treat the People: Access to Essential AIDS Medications A Primer for Health Professional Students.
Public health, innovation and intellectual property 1 |1 | Innovation and Access to Medicines: Case Study for HIV/AIDS and Hepatitis C Trends in voluntary.
Senate Health Care Committee Briefing: Hepatitis C Treatment Dan Lessler, MD Chief Medical Officer November 20, 2014.
Opportunities & Challenges: Expanding Access to Hepatitis C Treatment Gregg Alton Executive Vice President, Corporate & Medical Affairs.
Global Hepatitis C Guidelines 2014: recommendations for a public health approach Gottfried Hirnschall.
H EALTH INEQUALITIES IN THE NEW EU MEMBER STATES AND CANDIDATE COUNTRIES.
More on Generic Drugs Global Classrooms 2013 Rachel Hunkler.
Presentation to Civil Society meeting Maseru 12 August 2014.
Access to Innovation: Making Generic Versions of Newer Antiretrovirals Affordable Focusing on middle income countries Leena Menghaney, MSF Access Camapign.
Implementation of TRIPS Flexibilities In National IP Legislation For Strengthening Access To Medicines In Swaziland Workshop with MOH and stakeholders,
A very short introduction to patents & access to medicines.
How can Seychelles in future obtain affordable, good quality medicines for HIV/AIDS, Hepatitis C, cancer and other non-communicable diseases? Medical View.
Managing Hepatitis C: An Unprecedented Correctional Healthcare Challenge ASCA/CCHA meeting Phoenix, AZ RADM Newton E. Kendig Assistant Director/Medical.
Access to medicines, WTO TRIPS and Seychelles patent law Ellen ‘t Hoen, Medicines Law & Policy Seychelles September 2014.
Options for national/regional production of generic medicines Wilbert Bannenberg, MD MPH Zambia TRIPS workshop 3 Oct 2013.
Options for national/regional production of generic medicines Wilbert Bannenberg, MD MPH Lesotho TRIPS workshop 14 Aug 2014.
EXCLUSIVE MARKETING RIGHTS & MAIL-BOX APPLICATIONS BY Manish Kumar Prusty T. Harish.
The Medicines Patent Pool Ellen ‘t Hoen UNITAID Consultative Forum Geneva, 4-5 October 2011.
Getting the best treatment to the most people possible Enabling policies: threats & opportunities MSF Access Campaign.
A systematic review of hepatitis C clinical practice guidelines: Benefits, limitations and harms Lim, D., Siegel, E., Hepworth, J., Bain, T., and van Driel,
ACCESS TO MEDICINES - POLICY AND ISSUES
UNCTAD/CD-TFT 1 Exclusive Rights and Public Access – Flexibilities in International Agreements and Development Objectives The Public Health Example 21.
PATENT POOL & its CONCERNS PATENT POOL & its CONCERNS Manmohan A Amonkar 20 July 2010.
Managing Procurement and Logistics of HIV/AIDS Drugs and Related Supplies By Yvonne Nkrumah Legal Counsel, Ghana Food and Drugs Board.
Donors, prize funds and patent pools. KEI & UNU- MERIT Maastricht Workshop on Medical Innovation Prizes January 28th-29th 2008 Michelle Childs, Head of.
Ellen ‘t Hoen Médecins sans Frontières
Washington D.C., USA, July 2012www.aids2012.org Patent Oppositions in Argentina International AIDS Conference July 2012 M. Lorena Di Giano.
South Africa’s Acceptance of the Protocol Amending the TRIPS Agreement Xolelwa Mlumbi- Peter DDG: ITED 24 November 2015.
Uniting Forces for Access to Hepatitis C Treatment Global Epidemiology Global Epidemiology & Treatment Access Issues & Treatment Access Issues Tracy Swan.
Implementation of TRIPS Flexibilities In National IP Legislation For Strengthening Access To Medicines In Swaziland Workshop with MOH and stakeholders,
Strategies to increase access to high priced medicines and vaccines: lessons, new challenges and opportunities Judit Rius Sanjuan U.S. Manager & Legal.
Introduction: Intellectual Property Rights and its impact on access to medicines Anand Grover United Nations Special Rapporteur on Health East Africa Consultation,
ELPA Symposium Compassionate Use in Hepatitis C Saving lives of patients who cannot wait Thomas Berg Section of Hepatology Clinic for Gastroenterology.
Hepatitis C Drugs Market & Pipeline Drugs Analysis to 2019 With special emphasis on Hepatitis C Approved Drugs, Pipeline Drugs and Clinical Trial Analysis.
GLOBAL COOPERATION FOR IP AND DEVELOPMENT Esteban Burrone Head of Policy Medicines Patent Pool.
IMPROVING ACCESS AND INNOVATION IN HIV THROUGH VOLUNTARY LICENSING: THE EXPERIENCE OF THE MEDICINES PATENT POOL ICASA – Harare, Zimbabwe Session on Innovation.
Access to medicines challenges in Europe: What is wrong and the way forward Presented by: Rohit Malpani Director of Policy & Analysis, Access Campaign.
1 Special mechanism for the importation of pharmaceutical products under the TRIPS Agreement Carlos M. Correa.
PATENT POOL Anand Grover United Nations Special Rapporteur on Health East Africa Consultation, September 2010.
Access and/or Protection? Andrey Shastitko MSU, RANEPA.
VOLUNTARY PATENT POOLING FOR PUBLIC HEALTH A Model For Innovation And Access.
HCV ECAB, 20 May 2016 Brussels Urbano Sbarigia Global Market Access Leader.
Access to antiviral drugs for treating HCV for HIV-positive patients in Russia: results and recommendations of the registration, policy and procurement.
Moving towards a Patent Pool? XVII International AIDS Conference Satellite Forum, MSF, KEI, OXFAM (Mexico, 5 August 2008) Jorge Bermudez Executive-Secretary,
Mass treatment programmes for HIV, viral hepatitis and mdr-tb
How Pricing Affects Availability
Access to New Hepatitis C Treatment Tools:
3rd International HIV/Viral Hepatitis Co-Infection Meeting HIV/Viral Hepatitis: Improving Diagnosis, Antiviral Therapy and Access Sunday, 17 July.
Treating 35 million people with ART – where are we?
Making medicines, diagnostics and other commodities more affordable
Policy Options for Low and Middle Income Countries (LMIC)
The minimum cost to cure Hepatitis C - revisited
Contents Impact in terms of treatment affordability Impact in making new treatments available faster Impact in making needed new formulations.
Figure 1 Patients cured of HCV infection
Recommendations of working group, 17 Sept 2014
America’s $10 Billion Overspend on Sofosbuvir-Based Hepatitis C Treatment Resulting from Unmerited Patents Good afternoon. Pleased to be here to present.
Commonalities across treatments and diseases: A brief overview
Treat the world: Working united across diseases for quality and affordable treatment for all – AIDS 2018 TRIPS Flexibilities 0.2 Across Diseases Ellen.
A Guideline-Based Approach to HCV Care
Presentation transcript:

Access to HCV medicines and patent law Ellen ‘t Hoen, Medicines Law & Policy Seychelles September 2014

Background 185 million people across the world are infected with HCV; 150 million are chronically infected. The HCV pandemic is concentrated in middle-income countries (MICs) 15% of the 150 million people with chronic HCV live in high-income countries (HICs), 73% live in MICs 12% in low-income countries (LICs). It is estimated that HCV-related liver complications kill 350,000 people annually. Until recently treatment was cumbersome and not very effective Seychelles has approx. 440 cases of HCV

Direct Acting Antivirals New drug treatments: Direct Acting Antivirals (DAA) came to market in 2013 Simeprevir (formerly TMC435; trade name Olysio) marketed by J&J Sofosbuvir (Sovaldi) marketed by Gilead. Others in the pipeline Oral short course treatments weeks (to be taken together with one or two other products) Highly effective, provides a cure Recent WHO HEPC treatment guidelines recommend the use of DAAs.

The case of sofosbuvir Received marketing approval 6 Dec Marketed by Gilead. In HICs, sofosbuvir is sold USD1,000 per pill or USD84,000 per person for 12 weeks United States – estimated 5,367,834 persons are infected with HCV. GNI/capita: USD52,340 France, the cost of sofosbuvir is set at US$913 per pill (US$76,720 per person for 12 weeks). GNI/capita: US$41,750 In MICs, Gilead plans to sell sofosbuvir for at least US$2,000 (for a 12-week course).

HCV Treatment Cost RegimenCost (US$)Duration (weeks) Olysio+Pegasys+ribavirin106,67348 Incivec+Pegasys+ribavirn106,46848 Victrelis+Peintron+ribavirin95,84548 Sovaldi+Pegasys+ribavirin94,07812 Olysio+Pegasys+ribavirin86,51624 Incivek+Pegasys+ribaviron86,32124 Victrelis+Peintron+ribavirin85,25736 Victrelis+Pegintron+ribavirin64,82528

Gilead Gilead: “We will defend the patents, but at the same time, we are going to be pushing very hard to enable generic production in India with multiple companies.” talks-to-bring-hepatitis-c-drug-into-india/article ece talks-to-bring-hepatitis-c-drug-into-india/article ece Gilead’s website: “HCV is also a key therapeutic focus area for Gilead, and we are working on programs and partnerships to ensure that, worldwide, those patients for whom treatment with Sovaldi® (sofosbuvir) may be appropriate have access to it.”

Pricing in LMICs Tiered pricing in certain low and middle income countries Generic availability in 60 low income countries Egypt, US$900 per treatment course. GNI/pc $2980. MSF: target cost for treatment: 500$ This is possible

Cost of Production Source: 1/06/cid.ciu012.full.pdf+html 1/06/cid.ciu012.full.pdf+html Production cost for 12 week treatment Ribavirin$21 - $63 Daclatasvir (BMS)$10 - $30 Sofosbuvir (Sovaldi -Gilead)$68 - $136 Faldaprevir (BI)$100 - $210 Simeprevir (Olysio-J&J)$130 - $270

Generic sofosbuvir Low cost production of generic sofosbuvir is possible Gilead applied for patents in India Pre-grant opposition pending in India

Treatment cost Treatment of 440 full price– 37 mill $ 500$ - 220,000 $

Access Scenarios Originators lower the price to a level Seychelles an afford Originator grants voluntary licenses/ Medicines Patent Pool to generic manufacturers - Seychelles part of territory Patent not granted in India Patent not granted in Seychelles -> import from India Patent granted in Seychelles -> CL/GU -> import from India Patent granted in India -> Section 92(A) Indian Patents Act: CL for export to Seychelles Patent granted in Seychelles -> issue CL/GU SADC regional procurement -> larger orders to benefit from economies of scale – re-exportation from Seychelles to other SADC countries

Requirements TRIPS flexibilities included in Seychelles Patent Law. “Government use” of patents in procurement. Collaboration with other SADC countries to create economies of scale and demand by using the 30 th August 2003 waiver.